The effect of AVE 0991, nebivolol and doxycycline on inflammatory mediators in an apoE-knockout mouse model of atherosclerosis

Medical Science Monitor

Volumn 18, Issue 10, 2012, Pages

  Jawien, Jacek ^a   Toton Zuranska, Justyna ^a   Kus, Katarzyna ^a   Pawlowska, Malgorzata ^a   Olszanecki, Rafal ^a   Korbut, Ryszard ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Atherosclerosis model; AVE 0991; Doxycycline; Inflammatory markers; Nebivolol

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; DOXYCYCLINE; INTERLEUKIN 12; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; NADROPARIN; NEBIVOLOL; SERUM AMYLOID A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BLOOD ANALYSIS; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; MOUSE; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 84867621559     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883478     Document Type: Article

References (53)

1. Libby P, Ridker PM, Hansson GK: Progress and challenges in translaing the biology of atherosclerosis. Nature, 2011; 473(7347): 317-25
2. Piedrahita JA, Zhang SH, Hagaman JR et al: Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci, 1992; 89(10): 4471-75
3. Plump AS, Smith JD, Hayek T et al: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E - deficient mice created by homologous recombination in ES cells. Cell, 1992; 71(2): 343-53
4. Gupta S, Pablo AM, Jiang X et al: IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest, 1997; 99(11): 2752-61
5. Nakashima Y, Raines EW, Plump AS et al: Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol, 1998; 18(5): 842-51
6. Aiello RJ, Bourassa PA, Lindsey S et al: Monocyte chemoattractant protein1 accelerates atherosclerosis in apolipoprotein E-deficient mice.Arterioscler Thromb Vasc Biol, 1999; 19(6): 1518-25
7. Ni W, Egashira K, Kitamoto S et al: New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation, 2001; 103(16): 2096-101
8. Elhage R, Jawien J, Rudling M et al: Reduced atherosclerosis in interleukin- 18 deficient apolipoprotein E-knockout mice. Cardiovasc Res, 2003; 59(1): 234-40
9. Tenger C, Sundborger A, Jawien J, Zhou X: IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells. Arterioscler Thromb Vasc Biol, 2005; 25(4): 791-96
10. Zhou X, Nicoletti A, Elhage R, Hansson GK: Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation, 2000; 102(24): 2919-22
11. Cymerys M, Bogdański P, Pupek-Musialik D et al: Influence of hypertension, obesity and nicotine abuse on quantitative and qualitative changes in acute-phase proteins in patients with essential hypertension. Med Sci Monit, 2012; 18(5): CR330-36
12. Chhabra A, Aronow W, Ahn C et al: Incidence of new cardiovascular events in patients with and without peripheral arterial disease seen in a vascular surgery clinic. Med Sci Monit, 2012; 18(3): CR131-34
13. Karwowski W, Naumnik B, Szczepański M, Myśliwiec M: The mechanism of vascular calcification - a systematic review. Med Sci Monit, 2012; 18(1): RA1-11
14. Kus K, Gajda M, Pyka-Fosciak G et al: The effect of nebivolol on atherogenesis in apoE - knockout mice. J Physiol Pharmacol, 2009; 60(4): 163-65
15. Toton-Zuranska J, Gajda M, Pyka-Fosciak G et al: AVE 0991 - angiotensin-(1-7) receptor agonist, inhibits atherogenesis in apoE-knockout mice. J Physiol Pharmacol, 2010; 61(2): 181-83
16. Pawłowska M, Gajda M, Pyka-Fościak G et al: The effect of doxycycline on atherogenesis in apoE-knockout mice. J Physiol Pharmacol, 2011; 62(2): 247-50
17. Elhage R, Gourdy P, Jawien J et al: The atheroprotective effect of 17bestradiol depends on complex interactions in adaptive immunity. Am J Pathol, 2005; 167(1): 267-74
18. Jawien J, Gajda M, Mateuszuk L et al: Inhibition of nuclear factor-kappaB attenuates artherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol, 2005; 56(3): 483-89
19. Szczeklik A, Jawien J: Immunoglobulin E in acute phase response to surgical stress. Clin Exp Allergy, 1996; 26(3): 303-7
20. Olszanecki R, Jawien J, Gajda M et al: Effect of curcumin on atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol, 2005; 56(4): 627-35
21. Jawien J, Gajda M, Rudling M et al: Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/ LDLR - double knockout mice. Eur J Clin Invest, 2006; 36(3): 141-46
22. Kramkowski K, Mogielnicki A, Buczko W: The physiological significance of the alternative pathways of angiotensin II production. J Physiol Pharmacol, 2006; 57(4): 529-39
23. Montecucco F, Pende A, Mach F: The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm, 2009; 2009: 752406
24. Daugherty A, Manning MW, Cassis LA: Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest, 2000; 105(11): 1605-12
25. Jawien J, Nastalek P, Korbut R: Mouse models of experimental atherosclerosis. J Physiol Pharmacol, 2004; 55(3): 503-17
26. Lu P, Liu H, Yin H, Yang L: Expression of angiotensinogen during hepatic fibrogenesis and its effect on hepatic stellate cells. Med Sci Monit, 2011; 17(9): BR248-56
27. Benter IF, Yousif MH, Cojocel C et al: Angiotensin-(1-7) prevents diabetes- induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol, 2007; 292(1): 666-72
28. Kucharewicz I, Pawlak R, Matys T et al: Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension, 2002; 40(5): 774-79
29. Santos RA, Simoes e Silva AC, Maric C et al: Angiotensin- (1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA, 2003; 100(14): 8258-63
30. Clark MA, Diz DI, Tallant EA: Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells. Hypertension, 2001; 37(4): 1141-46
31. Wiemer G, Dobrucki LW, Louka FR et al: AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension, 2002; 40(6): 847-52
32. Pinheiro SV, Simoes E Silva AC, Sampaio WO et al: Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension, 2004; 44(4): 490-96
33. Lemos VS, Silva DM, Walther T et al: The endothelium dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. J Cardiovasc Pharmacol, 2005; 46(3): 274-79
34. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 2005; 352(16): 1685-95
35. Weiss R: Nebivolol: a novel beta-blocker with nitric oxide induced vasodilatation. Vasc Health Risk Manag, 2006; 2(3): 303-8
36. Broeders MA, Doevendans PA, Bekkers BC et al: Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production Circulation, 2000; 102(6): 677-84
37. Dessy C, Saliez J, Ghisdal P et al: Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation, 2005; 112(8): 1198-205
38. Mollnau H, Schulz E, Daiber A et al: Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol, 2003; 23(4): 615-21
39. Wolf SC, Sauter G, Preyer M et al: Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after baloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiol Biochem, 2007; 19(1-4): 129-36
40. Baumhakel M, Schlimmer N, Buyukafsar K et al: Nebivolol, but not metoprolol, improves endothelial function of the corpus cavernosum in apolipoprotein e-knockout mice. J Pharmacol Exp Ther, 2008; 325(3): 818-23
41. Flather MD, Shibata MC, Coats AJ et al: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J, 2005; 26(3): 215-25
42. Tzemos N, Lim PO, MacDonald TM: Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation, 2001; 104(5): 511-14
43. Wei-Kang G, Dong-Liang Z, Xin-Xin W et al: Actin cytoskeleton modulates ADMA-induced NF-kappaB nuclear translocation and ICAM-1 expression in endothelial cells. Med Sci Monit, 2011; 17(9): BR242-47
44. Weakley S, Jiang J, Lu J et al: Natural antioxidant dihydroxybenzyl alcohol blocks ritonavir-induced endothelial dysfunction in porcine pulmonary arteries and human endothelial cells. Med Sci Monit, 2011; 17(9): BR235-41
45. Johnson JL, Fritsche-Danielson R, Behrendt M et al: Effect of broadspectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovasc Res, 2006; 71(3): 586-95
46. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest, 1994; 94(6): 2493-503
47. Piotrowski W, Gorski P, Pietras T et al: The selected genetic polymorphisms of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis. Med Sci Monit, 2011; 17(10): CR598-607
48. Higashikata T, Yamagishi M, Higashi T et al: Altered expression balance of matrix metalloproteinases and their inhibitors in human carotid plaque disruption: results of quantitative tissue analysis using realime RT-PCR method. Atherosclerosis, 2006; 185(1): 165-72
49. Michalska M, Gluba A, Mikhailidis D et al: The role of polyphenols in cardiovascular disease. Med Sci Monit, 2010; 16(5): RA110-19
50. Kuzuya M, Nakamura K, Sasaki T et al: Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol, 2006; 26(5): 1120-25
51. Hanemaaijer R, Visser H, Koolwijk P et al: Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res, 1998; 12(2): 114-18
52. Gapski R, Hasturk H, Van Dyke TE et al: Systemic MMP inhibition for periodontal wound repair: results of a multicentre randomized-controlled clinical trial. J Clin Periodontol, 2009; 36(2): 149-56
53. Madan M, Bishayi B, Hoge M, Messas E, Amar S: Doxycycline affects diet- and bacteria-associated atherosclerosis in an ApoE heterozygote murine model: cytokine profiling implications. Atherosclerosis, 2007; 190(1): 62-72